Bioray Biotech Co Ltd

Bioray Biotech Co Ltd exhibits a capital structure with a debt-to-equity ratio of 0.2, indicating a relatively conservative leverage position. The company's liquidity is characterized as medium, with a current ratio of 6.98, suggesting strong short-term liquidity. However, the valuation snapshot reveals a price-to-earnings ratio of 543.28, which is significantly elevated, reflecting either high investor expectations or potential earnings concerns.

Profitability metrics for Bioray Biotech Co Ltd are modest, with a return on equity of 0.0024 and a return on assets of 0.0018, both of which are below the typical thresholds for industry-leading performance. The company's operating income is negative at -4.3 million TWD, indicating operational challenges despite a positive net income of 1.0 million TWD. This discrepancy suggests that non-operating income or gains may be contributing to the net profit.

The company's revenue concentration is not explicitly detailed in the available data, but the absence of segment-specific revenue breakdowns implies a lack of diversification in its product or geographic exposure. This could pose a risk if the company's primary market experiences a downturn.

Bioray Biotech Co Ltd's growth trajectory is uncertain, as the outlook data does not provide specific numeric deltas for the current or next fiscal year. The company's revenue history shows a total revenue of 201.7 million TWD, but without comparative data, it is difficult to assess year-over-year performance. The risk assessment indicates a low dilution potential, but the presence of a negative net cash position after subtracting total debt raises concerns about liquidity.

Recent events and filings for Bioray Biotech Co Ltd are not detailed in the provided data, which limits the ability to assess any recent strategic moves or operational changes. The absence of transcript data or recent filings suggests a lack of public disclosure activity, which could affect investor confidence.